Philipp Lachenmann: DELPHI Rationale


Schering Prize 2007

Dr. Kathrin Schneider

"Novel natural products for human health"

Sanofi-Aventis Germany GmbH

Dr. Kathrin Schneider (born in 1979) studied chemistry at the University of Tuebingen until 2004. In November of that year, she began her thesis work under the supervision of Prof. Dr. Roderich Süßmuth at the Department of Chemistry at the Technical University of Berlin. In late 2007, she completed her doctoral thesis on “Structure Elucidation of Proximicins, Furan Analogues of Netropsine from the Marine Actinomycetes Verrucosispora and Studies on the Metabolite Production of the Plant Growth Promoting Bacillus Amyloliquefaciens FZB42.“ Drawing on both classical screening and modern genomic approaches, Kathrin Schneider’s thesis has made a contribution to the structure elucidation and classification of novel natural substances. She currently heads a lab at Sanofi-Aventis Deutschland GmbH.



Live-Debatte: Was tun, wenn Niere, Leber und Herz knapp werden?

09.03.2018, Berlin | Während mehr als 10.000 Menschen in Deutschland dringend auf ein Spenderorgan warten, sinkt...

Big Data Means Big Responsibility. The Use of Data in the Healthcare Sector

24.02.2018, Erlangen | The digitalization of medicine is making big strides. The integration of previously distinct...

Visions of Synthetic Biology

16.02.2018, Berlin | Life is what you make it – this is the motto of synthetic...